Publications by authors named "M Sarih"

To assess the impact of the SARS-CoV-2 booster dose on the immune response against COVID-19, we conducted a cross-sectional study in the Casablanca-Settat region of Morocco. The study included 2,802 participants from 16 provinces, all of whom had received three doses of a SARS-CoV-2 vaccine. IgG antibodies targeting the S1 RBD subunit of the SARS-CoV-2 spike protein were quantified using the SARS-CoV-2 IgG II Quant assay and measured on the Abbott Architect i2000SR instrument.

View Article and Find Full Text PDF
Article Synopsis
  • - The study identifies the JN.1 variant of SARS-CoV-2 in Morocco through genomic sequencing.
  • - Four clinical samples were analyzed, including nasopharyngeal swabs from one female and three male patients.
  • - The Illumina COVIDSeq Test was utilized for a thorough genomic analysis of the samples.
View Article and Find Full Text PDF
Article Synopsis
  • SARS-CoV-2 symptoms range from none to severe, with some cases involving serious complications and death, and genetic factors may impact infection risk and severity.
  • The study focuses on specific IL-6 gene variants (rs1800795 and rs1800797) in a Moroccan population to assess their link to virus susceptibility and COVID-19 severity.
  • While no significant links were found between the gene variants and susceptibility, specific haplotypes (GC* and AG*) were associated with a reduced risk of SARS-CoV-2 infection.
View Article and Find Full Text PDF

Assessing the prevalence of SARS-CoV-2 IgG positivity through population-based serological surveys is crucial for monitoring COVID-19 vaccination efforts. In this study, we evaluated SARS-CoV-2 IgG positivity within a provincial cohort to understand the magnitude of the humoral response against the SARS-CoV-2 vaccine and to inform evidence-based public health decisions. A community-based cross-sectional seroprevalence study was conducted, involving 10,669 participants who received various vaccines (two doses for BBIBP-CorV/Sinopharm, Covishield vaccine, and Pfizer/BioNTech, and one dose for Johnson & Johnson's Janssen COVID-19 vaccine).

View Article and Find Full Text PDF

Background: Mosquitoes of the Culex pipiens complex are widely distributed vectors for several arboviruses affecting humans. Consequently, their populations have long been controlled using insecticides, in response to which different resistance mechanisms have been selected. Moreover, their ecological preferences and broad adaptability allow C.

View Article and Find Full Text PDF